Search

Immunotherapy delivered by Blinatumomab improves survival in acute lymphoblastic leukaemia patients

Adult patients with acute lymphoblastic leukemia (ALL) can achieve disease control in 90% of cases with intense chemotherapy but only half of these responders will be cured.

Read more

Regulatory affairs & scientific relations

EHA’s regulatory work: European Medicines AgencyMost of EHA’s regulatory work entails collaboration with the European Medicines Agency (EMA).

Read more

IVDR resources

IVD Taskforce Videos:Konstanze Döhner

\
 

Monika Brüggemann

IVDR Sessions:

HemaSphere articles:
Critical Implications of IVDR for Innovation in Diagnostics: Input From the BioMed Alliance Diagnostics Task Force
The New EU Regulation on In Vitro Diagnostic Medical Devices: Implications and Preparatory Actions for Diagnostic Laboratories
EU-Wide Access to…

Read more

Grants & abstract awards

EHA Travel GrantsThe call for travel grant applications closed on March 1, 2025 (23:59 CET). The grants will only be available for investigators with accepted abstracts, submitted during the regular abstract submission.

Read more

Improved survival for adult Acute Lymphoblastic Leukemia (ALL) patients

Historical survival for patients 18-45 years with ALL is approximately 40 %. However the event free survival for ALL patients 18-45 years has improved to 73% following implementation of the NOPHO ALL2008 protocol in July 2008.

Read more

Publications

The publications of the ESLHO networks can be found on the following pages:

EuroFlow publications
EuroMRD publications
EuroClonality publications
The publications from 2023 are also listed below.

Read more

EHA-HKSH Hematology Tutorial on Lymphoid Malignancies

Dates: April 25-26, 2020 
Location: Hong Kong
Chairs: G Gaidano, J Gribben, MF Law

In 2020 EHA will co-organize the first Hematology Tutorial in Hong Kong, together with the Hong Kong Society of Haematology (HKSH).

Read more